Recursion Pharmaceuticals (RXRX) Change in Accured Expenses (2020 - 2026)

Recursion Pharmaceuticals has reported Change in Accured Expenses for 7 years, with the latest figure at -$18.5 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 30.61% year-over-year to -$18.5 million; the trailing twelve-month figure through Mar 2026 stood at $733000.0 (up 133.09% YoY), and the FY2025 full-year result was -$7.4 million, down 234.21% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$18.5 million, down from $15.8 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $15.8 million in Q4 2025, with the low at -$26.6 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged -$835058.8 across 5 years, with a median of $2.8 million in 2023.
• The largest YoY upside for Change in Accured Expenses was 641.26% in 2022 against a maximum downside of 11680.0% in 2022.
• Recursion Pharmaceuticals' Change in Accured Expenses stood at $12.2 million in 2022, then plunged by 77.12% to $2.8 million in 2023, then surged by 278.01% to $10.5 million in 2024, then jumped by 50.56% to $15.8 million in 2025, then slumped by 216.49% to -$18.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$18.5 million (Q1 2026), $15.8 million (Q4 2025), and -$8.0 million (Q3 2025), per Business Quant data.